@article {HIRABAYASHI2227, author = {KOICHI HIRABAYASHI and RYU YANAGISAWA and SHOJI SAITO and YUMIKO HIGUCHI and TERUTSUGU KOYA and KENJI SANO and SHIGEO KOIDO and MASATO OKAMOTO and HARUO SUGIYAMA and YOZO NAKAZAWA and SHIGETAKA SHIMODAIRA}, title = {Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors}, volume = {38}, number = {4}, pages = {2227--2234}, year = {2018}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Wilms{\textquoteright} tumor 1 (WT1) peptide-based vaccination has been reported for its potential usefulness in targeting several cancers. The adjuvant drug OK-432 is known to have potent immunomodulation and therapeutic properties when applied in cancer treatment and may, thus, be important to trigger the appropriate immunological response in paediatric patients with a solid tumor that are vaccinated with a WT1 peptide. Patients and Methods: Paediatric patients with a solid tumor were vaccinated with a WT1 peptide and OK-432 once every 2 weeks, for a total of seven times. Results: Of the 24 patients, 18 completed the scheduled vaccinations. Sixteen patients had local skin symptoms and/or fever. In 1 patient, anaphylactic symptoms emerged at the time of the final injection, but these quickly subsided after the treatment. WT1-specific immunological responses were observed in 4 patients (22.2\%). WT1 and HLA class I expression were confirmed in 100\% and 85\% of primary tumors, respectively. Conclusion: WT1 peptide vaccine therapy combined with OK-432 appears to be relatively safe for children. However further studies in a larger number of patients are necessary to confirm its safety and efficacy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/4/2227}, eprint = {https://ar.iiarjournals.org/content/38/4/2227.full.pdf}, journal = {Anticancer Research} }